Dr Victoria Jane Jackson-Patel

Selected publications and creative works (Research Outputs)

As of 29 October 2020 there will be no automatic updating of 'selected publications and creative works' from Research Outputs. Please continue to keep your Research Outputs profile up to date.
  • Jackson-Patel, V. J. (2018). Inhibiting the Epidermal Growth Factor Receptor (EGFR) to improve clinical outcomes for patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) The University of Auckland. ResearchSpace@Auckland.
  • Silva, S., Jackson, V., Guise, C., Abbattista, M., Bull, M., Grey, A., ... Pearce, T. (2015). Preclinical efficacy of tarloxotinib bromide (TH­4000), a hypoxia­activated EGFR/HER2 inhibitor: Rationale for clinical evaluation in EGFR mutant, T790M-­negative NSCLC following progression on EGFRTKI therapy. Paper presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts. 5 November - 9 November 2015. Molecular Cancer Therapeutics. (pp. 2).
    Other University of Auckland co-authors: Gus Grey, Bob Anderson, Amir Ashoorzadeh, Adam Patterson, Jeff Smaill, Matthew Bull

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 005
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand